一个网络驱动的计算框架,用于识别FDA批准的药物在异质性脑癌中重新使用.
1The Institute of Mathematical Sciences (IMSc), Chennai, India.
Frontiers in molecular biosciences
|March 5, 2026
概括
这项研究开发了一个计算框架,使用FDA批准的药物用于大脑癌症重定位. 这种新方法以很高的准确性确定了三种优先药物 - - 梅弗洛昆,克洛纤维酸和阿米拉里辛A.
科学领域:
- 在瘤学瘤学.
- 计算生物学 计算生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 大脑癌症表现出显著的异质性,由于失调的信号通路使治疗策略复杂化.
- 像EGFR,BRAF,TP53和VEGFR2这样的关键途径组件是合理的药物选择和重新利用的关键目标.
- 现有的药物重定向协议通常使用食品和药物管理局 (FDA) 批准的药物.
研究的目的:
- 开发一个网络驱动的计算框架,用于大脑癌症药物重用.
- 通过分析FDA批准药物的分子特征来确定新的治疗策略.
- 通过合理的药物选择来解决脑癌治疗的复杂性.
主要方法:
- 设计了一个使用已识别的途径组件来定义分子签名的协议.
- 开发了两个应用程序:"in-mac"用于分子概况生成和"ReBrain"用于基于网络的药物重定向分析.
- 使用机器学习模型验证了框架,并分析了2809个FDA批准的药物分子.
主要成果:
- "in-mac"和"ReBrain"平台成功地分析了2809种FDA批准的药物,生成了15维的活动特征.
- 使用分子配置文件构建了一个网络,使得在分析和精细化.
- 基于个人资料网络的方法在治疗与大脑相关疾病的药物重定位方面实现了70% - 95%的准确性.
结论:
- 确定了针对脑癌的三种优先重定向药物:美弗洛,纤维酸和阿米拉里辛A.
- 这项研究表明,对于各种脑瘤来说,潜在的协同药物组合是可能的.
- 开发的应用程序 ("in-mac"和"ReBrain") 是公开可访问的,用于更广泛的研究.
更多相关视频
06:50Advancements in the Metabolic Profiling of Three-Dimensional Brain Tumor Spheroids for Drug Screening
Published on: September 5, 2025
561
03:08Using Human Differentially Expressed Gene Lists to Perform Downstream Pathway Enrichment Analysis and Target Prioritization
Published on: October 3, 2025
1.0K
相关概念视频
Drug Discovery: Overview
12.5K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
12.5K
Pharmacogenomics: Identification of New Drug Targets
55
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
55
